Effectiveness of Low-Dose Atropine (0.01% to 0.05%) in Reducing Myopia Progression: A Systematic Review and Meta-Analysis
Abdullah S Alqahtani, Salma Hamdan Almarwani, Basmah Saeed Alweal, Mohammad Albadri, Lama Nasser Alghamdi, Bushra Wadi Bin Saddiq, Ahmed Salah Morad · 2026
Read Effectiveness of Low-Dose Atropine (0.01% to 0.05%) in Reducing Myopia Progression: A Systematic Review and Meta-Analysis by Abdullah S Alqahtani, Salma Hamdan Almarwani, Basmah Saeed Alweal, Mohammad Albadri, Lama Nasser Alghamdi, Bushra Wadi Bin Saddiq, Ahmed Salah Morad (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13160674.txt.
Description
Abdullah Alqahtani and co-authors present a 2026 review of low-dose atropine drops for slowing shortsightedness in children. The drops are widely used, but trials used different strengths and reported mixed results. The authors pooled randomized trials to judge both benefit and safety across the low-dose range.
The search covered four databases in January 2025 and followed standard review rules. Trials from 2019 to 2024 enrolled children aged 4 to 18 with worsening myopia. Strengths from 0.01 to 0.05 percent were compared with placebo or other controls. Reviewers extracted data and graded bias risk on their own. Pooled results estimate how much each strength slows the eye's growth. Parents and doctors gain a firmer basis for choosing a dose.
Catalog record
| CREATOR | Abdullah S Alqahtani, Salma Hamdan Almarwani, Basmah Saeed Alweal, Mohammad Albadri, Lama Nasser Alghamdi, Bushra Wadi Bin Saddiq, Ahmed Salah Morad |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |